Securisyn Medical Awarded a $1.95M SBIR Fast-Track Grant to Develop SolidAIRity Flex™ Pediatric and Neonatal Endotracheal Securement Devices for Improved Clinical Safety
By: Colorado BioScience Association Date: 09/22/2021
Securisyn Medical LLC, a provider of novel breathing and smooth tube and catheter securement products dedicated to improving patient outcomes, today announced the award of a Fast-Track Small Business Innovation Research (SBIR) grant by the Eunice Kennedy National Institute of Child Health and Human Development (NICHD). The NICHD, which is part of the National Institutes of Health (NIH), awarded the collaborative grant to support Securisyn Medical’s development and clinical testing of its novel neonatal and pediatric endotracheal securement devices to reduce the unintentional removal of a patient’s life-sustaining breathing tube, a life-threatening complication referred to as Unplanned Extubation (UE). This grant award was made in partnership between Securisyn Medical, Minnesota HealthSolutions Corporation (MinnHealth), based in Minneapolis/St. Paul, MN), and The Children’s Hospital of Los Angeles (CHLA). Nick Rydberg, MinnHealth VP of Engineering, will serve as the principal investigator (PI), joined by clinical investigators Robinder G. Khemani, MD, MSc and Narayan Iyer, MD, from CHLA.
Mechanical ventilation through an endotracheal tube is routine in the PICU and NICU environments and has contributed to improved survival and reduced morbidity. However, neonatal patients, infants, and other children of all ages have unique challenges with endotracheal tube securement and are at particularly elevated risk for unplanned extubation due to anatomic and physiologic factors. UE is common in mechanically ventilated patients in the NICU (Average = 18.2%; Range 1.0% – 80.8%) and the PICU (Average 8%; Range 0.8% – 18.5%) (1). Unplanned extubation is potentially devastating and costly, often leading to a variety of serious, life-threatening cardiovascular and respiratory complications, increased hospital length of stay (16.5 days vs 10 days), increased attributable hospital cost per event by $36,000, and is the fourth most common adverse event in NICUs in the United States.
Find out more in the press release.